
    
      A Multinational, Multicentre, Randomised, Double Blind, Placebo-Controlled, 2-way Crossover
      Study to Evaluate the Efficacy and Safety of Glycopyrrolate Bromide Administered Via pMDI
      (CHF 5259), for the Treatment of Patients With Chronic Obstructive Pulmonary Disease
    
  